Clinical Trial: Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916416) titled 'Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma' on March 31.

Brief Summary: By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Classical Hodgkin Lymphoma

Intervention: DRUG: Pembrolizumab

6 doses of 200mg Pembrolizumab iv as single agent every three weeks followed by radiotherapy 20Gy

Recruitment Stat...